50% Off Your Order*

Easter Savings!!

Take 50% Off!

Sermorelin-5mg

Availability: In stock

$0.00
  • Free Priority Shipping
  • With Purchase over $99 | USA ONLY

Buy Sermorelin 5mg :

Unit Size 5 mg/vial
Unit Quantity 1 vial
Purity (Mass Spectrometry and UV) 99.2%
Sequence H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-
Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Molecular Formula C149H246N44O42S
Molecular Mass 3355.84
Appearance Lyophilized White Powder
Source Chemical Synthesis
Storage
Lyophilized Sermorelin is Stable at room
Temperature for 90 days, however it is best to store
in a freezer below - 8c for any extended period of time.
After reconstitution Sermorelin should be
refrigerated at temperatures not to exceed 35 F.
Terms The products we offer are intended for laboratory
research use only. Please familiarize yourself with
our terms of service prior to ordering.

 

Sermorelin is a synthetic analog of the growth hormone-releasing hormone (GHRH) naturally found in the human body. GHRH contains a total of 44 amino acids — sermorelin contains only the first 29 amino acids of GHRH and has a molecular mass of 3357.9 g/mol. Despite its small size, sermorelin is able to bind efficiently to the GHRH receptor. In fact, studies show that sermorelin binds to GHRH receptors at extremely low concentrations, with a binding affinity around 50 times as potent as GHRH.1 Sermorelin also activates the hypothalamic-pituitary-somatotropic axis, as opposed to the ghrelin/growth hormone secretagogue (GHS) receptor pathway.2 With this, sermorelin is a powerful tool to use in vitro and in vivo studies. Endogenously, GHRH stimulates the anterior pituitary gland to release human growth hormone (HGH). Sermorelin both increases growth hormone levels and modulates the extends the time of growth hormone release.3 Sermorelin has a half-life of around 12 minutes, but it can stimulate growth hormone release for around 2 hours.4 One study using rats found that intravenous administration of sermorelin increased growth hormone release by 17% over the course of 15 minutes, compared to controls.5 Sermorelin was shown to increase levels of insulin-like growth factor 1 (IGF-1), improve insulin sensitivity, and increase lean muscle mass.2Another study found that the peptide blocks the growth of glioma cells in people with recurrent glioma. Sermorelin was found to prevent glioma cells from progressing through the cell cycle and dividing.6 While many reports and research studies show that sermorelin can be used as a treatment for growth hormone deficiency or other diseases/conditions, this formulation is not approved for these purposes. Sermorelin is synthesized and commercially distributed for laboratory research purposes only.

Sermorelin is available as a lyophilized white powder at a concentration of 5 mg/vial.

References: 1. Lance VA, Murphy WA, Sueiras-Diaz J, Coy DH. Super-active analogs of growth hormone-releasing factor (1-29) amide. Biochem Biophys Res Commun. 1984; 119(1):265-272. 2. Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar; 9(Suppl 2):S149-159. 3. Grossman A, et al. Responses to analogues of growth hormone-releasing hormone in normal subjects, and in growth-hormone deficient children and young adults. Clin Endocrinol (Oxf). 1984; 21(3):321-330. 4. Esposito P, Barbero L, Caccia P, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003 Sep; 55(10):1279-91. 5. Bańkowski K, Witkowska E, Michalak OM, Sidoryk K, Szymanek E, Antkowiak B, Paluch M, Filip KE, Cebrat M, Setner B, Szewczuk Z, Stefanowicz P, Cmoch P, Izdebski J. Synthesis, biological activity and resistance to proteolytic digestion of new cyclic dermorphin/deltorphin analogues. Eur J Med Chem. 2013;63:457-67. 6. Chang Y, Huang R, Zhai Y, et al. A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med. 2021 Mar; 9(5):406.